DISCERN™, A Highly Accurate, Minimally Invasive Test To Diagnose Alzheimer’s Disease
Frank Amato, CEO and President, SYNAPS Dx, which offers DISCERN™, the first highly accurate, minimally invasive test supporting a clinician’s definitive diagnosis of AD versus other forms of dementia, even in people recently diagnosed with dementia. DISCERN is commercialized under the Clinical Laboratory Improvement Amendments (CLIA) and is reimbursed by Medicare.
Learn:
- What is SYNAPS Dx, working on.
- What Discern is.
- How often should a person who is diagnosed with dementia, be reassessed.
- If Doctors really know what types of support are available to families.
- What is the Fingers Study?
- How we can get services, products, and tools to Doctors so they can pass along to families.
- Is the Discern test covered by insurance?
Listen Live or Listen at Your Convenience Tuesday, November 14th, 2023 2 pm EST, 1 pm CST, 12 pm MST, 11 am PST & 7 pm London GMT, 9 pm South Africa SAST, and on the 15th at 6 am in Australia AEDT